Secretin-enhanced Magnetic Resonance Imaging (S-MRI) for Pancreatic Cancer Detection

• Status: Withdrawn
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to evaluate the utility of secretin-enhanced MRI (S-MRI) in detecting and measuring pancreatic lesions in patients with known adenocarcinoma or Intraductal papillary mucinous neoplasm (IPMN) lesions. The hypothesis is that S-MRI is superior to MRI without secretin enhancement (N-MRI) in increasing tumor conspicuity, allowing for improved identification and more accurate measurement of lesions or precursor lesions in the pancreas.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Elizabeth Hecht
• Treatments: Secretin

Criteria

Inclusion Criteria:

• 18 years of age or older

• Histologically confirmed IPMN/pancreatic adenocarcinoma by biopsy or fine needle or suspected IPMN/pancreatic adenocarcinoma based on imaging

• Scheduled for surgical resection

• Willingness to provide informed consent.

Exclusion Criteria:

• Any contraindication to magnetic resonance imaging (MRI), including but not limited to implanted metal devices (e.g. pacemaker, berry aneurysm clips, neural stimulator or cochlear implants)

• Unresectable tumor

• Other abdominal neoplasm in addition to neoplasm in pancreas

• Contraindication to surgery, including but not limited to recent myocardial infarction (MI) (within 6 weeks) or poor pulmonary function

• History of sensitivity to secretin

• Pregnancy

• Estimated glomerular filtration rate (GFR) < 30 mL/min/1.73 m2 (as per Modification of Diet in Renal Disease (MDRD) Study equation)

• Unwillingness or inability to provide informed consent.